Radiation Oncology

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Ron Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.

Establishing guideline harmonization and practice standardization may help promote the safe and consistent delivery of radiopharmaceutical therapies.

Due to certain errors in the 2026 PFS Final Rule pre-publication, ACRO has issued a statement while awaiting the publication of the 2026 HOPPS Final Rule.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Combinations of antiangiogenic therapy with chemoimmunotherapy may feasibly be shifted forward in real-world extensive-stage small cell lung cancer care.

The Nuclear Medicine Clarification Act seeks to increase transparency in reporting potentially high-dose extravasations in administering radiation.

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

Data from the phase 3 ROADS trial show significant gains in efficacy without increases in safety concerns following the use of GammaTile.

Patients with full-thickness or outer full-thickness stromal invasion following surgery had improved PFS when treated with SIB radiotherapy.

Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.

Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.

The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.

The SKYSCRAPER-03 trial revealed that tiragolumab plus atezolizumab failed to improve progression-free survival compared with durvalumab in NSCLC.

Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.

Researching the feasibility of consolidating extensive information into a unified cancer database is the “tip of the iceberg”, said Leila Tchelebi, MD.